Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of IMM0306 in IgG4-related disease
CTR20262001Phase 3Active
- Sponsor
- ImmuneOnco
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of IMM0306S in IgG4-related disease (IgG4-RD), sponsored by ImmuneOnco. Started Jul 2026; status: active.
02
Drugs
IMM0306S
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on CTR20262001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262001.